AaiPharma inquiry
Executive Summary
AaiPharma may delay filing its Form 10-K while an independent committee investigates "unusual sales" for the bronchodilatorBrethine and pain agent Darvocet...
You may also be interested in...
AaiPharma “Unusual Sales” May Prompt Subpoenas; CEO Steps Down
An investigation into sales of aaiPharma products may result in subpoenas from the Securities & Exchange Commission and the U.S. Attorney's Office, the company said
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.